Research And Development

Title

EVALUATING SERUM BIOMARKERS LIVERFAST SURROGATES OF LIVER FIBROSIS AND STEATOSIS COULD IDENTIFY RISKS IN A CLINICAL POPULATION EXPERIENCING SARS-COV2 INFECTION (COVID).

Lead Author

Dr. Maryna Raskin

Study Population

Miscellaneous n=10,623
LIVERFASt™ & LIVERFASt Select

Conclusion

LIVERFASt™ Steatosis and Fibrosis scores are NITs that could be used to screen populations at risk of MetS and liver disease to identify those at risk of COVID-19.

Location

Health Catalyst US

Title

SIMULATING CLINICAL CONFIDENCE INTERVALS FOR BLACK-BOX ALGORITHMIC PREDICTIONS OF LIVER STEATOSIS.

Lead Author

Dr. Brian Cohn

Study Population

IT simulations
10,000 replicates per biomarker

Conclusion

Noise injection allows for nuanced tailoring & interpretation of results inferred by an AIA. We equip clinicians with an interactive tool to contextualize therapeutic expectations & aid in patient education towards adherence endpoints. In effect, providing a new, nuanced view of how AIA assess LD.

Location

Fibronostics US

Title

MACHINE LEARNING TECHNOLOGY FOR EVALUATION OF LIVER FIBROSIS, INFLAMMATION ACTIVITY AND STEATOSIS (LIVERFASt™).

Lead Author

Abhishek Aravind

Study Population

NAFL to advanced NASH n=2862
LIVERFASt™

Conclusion

The modified SAF scoring system generated by LIVERFASt™ provided a simple & convenient diagnosis of NAFLD & NASH, and staging of the three liver lesions as shown in a cohort of SEA.

Location

Fibronostics Singapore

Title

PREDICTIVE VALUE OF NON-INVASIVE METHODS LIVERFAST, ACOUSTIC RADIATION FORCE IMPULSE (ARFI), FIB-4 & APRI TO IDENTIFY THE NATURAL PHASES OF CHB INFECTION FROM NUH CHB STUDY COHORT OF SINGAPORE.

Lead Author

Prof. Lim Seng Gee

Study Population

CHB n=724, LIVERFASt™

Conclusion

LF-Fibrosis & LF-Activity are reliable tools for screening HBV infected patients & for detecting phase-related liver disease, with better NPV than APRI or FIB-4. Management of HBV pts could be improved by LF tests.

Location

National University Health System (NUHS) Singapore

Title

COMPARATIVE ASSESSMENT LIVER LESIONS USING NON-INVASIVE SERUM BIOMARKERS LIVERFASt™, FIB4, APRI AND LIVER STIFFNESS MEASUREMENT (LSM, FIBROSCAN) IN CHRONIC HEPATITIS C (CHC) PATIENTS WITH LIVER BIOPSY.

Lead Author

Prof. Wattana

Study Population

CHC n=100, LIVERFASt™ & Biopsy

Conclusion

	Fibrosis	Activity
LIVERFASt™	0.806	0.700
TE	0.810	NA
FIB4	0.754	NA
APRI	0.796	NA

Srinagarind Hospital, Khon Kaen University Thailand

Title

COMPARATIVE PERFORMANCES OF LIVERFAST, VTCE (FIBROSCAN) & OTHER SERUM NITs FOR THE DIAGNOSIS OF ADVANCED CLD IN NAFLD PATIENTS FROM A COHORT WITH LIVER BIOPSY.

Lead Author

Prof. Victor De Ledinghen

Study Population

NAFLD n=583, LIVERFAStTM & Biopsy

Conclusion

LIVERFASt™ – Fibrosis is a NIT for the diagnosis of advanced disease in NAFLD patients either in T2DM or non-T2DM pts. This score could be very useful to select patients for CT & as screening test in general population.

Non-T2DM (n=287)	0.827
T2DM (n=301)	0.788

Location

University Hospital Center (CHU), Bordeaux France